Arcellx (ACLX) Other Non-Current Liabilities (2021 - 2025)
Arcellx's quarterly Other Non-Current Liabilities came in at $3.4 million in Q1 2025, down 77.78% year-on-year from $15.5 million in Q1 2024, and down 60.0% quarter-over-quarter from $8.6 million in Q4 2024.
Arcellx has reported Other Non-Current Liabilities for 4 years, with the latest figure at $3.4 million in Q1 2025.
- For the quarter ending Q1 2025, Other Non-Current Liabilities fell 77.78% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2025 stood at $3.4 million (down 77.78% YoY), and the FY2024 full-year result was $8.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2025 stood at $3.4 million, down from $8.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $15.5 million in Q1 2024, with the low at $117000.0 in Q2 2022.
- Average Other Non-Current Liabilities over 4 years is $7.2 million, with a median of $6.0 million recorded in 2024.
- Peak annual rise in Other Non-Current Liabilities reached 77.78% in 2025, while the deepest fall reached 77.78% in 2025.
- Tracing ACLX's Other Non-Current Liabilities over 4 years: stood at $178000.0 in 2021, then sank by 34.27% to $117000.0 in 2022, then jumped by 7244.44% to $8.6 million in 2024, then slumped by 60.0% to $3.4 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $3.4 million (Q1 2025), $8.6 million (Q4 2024), and $15.0 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | 8.59 Mn |
| Sep 30, 2024 | 15.05 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | 15.47 Mn |
| Jun 30, 2022 | 117,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 178,000.00 |